PRVL Prevail Therapeutics Inc.

18.12
+0.03  (+0%)
Previous Close 18.09
Open 18
Price To Book 3.39
Market Cap 617,928,584
Shares 34,102,019
Volume 72,811
Short Ratio
Av. Daily Volume 122,403
Stock charts supplied by TradingView

NewsSee all news

  1. Prevail Therapeutics Provides PR001 Program Update

    PR001 Administered to International Type 2 Gaucher Disease Patient Via Compassionate Use Pathway Company Advancing its Phase 1/2 Clinical Trial for the Treatment of Neuronopathic Gaucher Disease and Expects to Initiate

  2. Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease

    NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL) ("Prevail" or the "Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients

  3. Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation

    NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative

  4. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  5. Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of Directors

    NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated 1H 2020.
PR001
Neuronopathic Gaucher disease
Phase 1/2 trial has been initiated - noted December 2019. Interim data due 2H 2020.
PR001 - Propel
Parkinson’s disease with GBA1 mutation
Phase 1/2 trial to be initiated 1H 2020.
PR006
Frontotemporal Dementia Patients with GRN Mutations

Latest News

  1. Prevail Therapeutics Provides PR001 Program Update

    PR001 Administered to International Type 2 Gaucher Disease Patient Via Compassionate Use Pathway Company Advancing its Phase 1/2 Clinical Trial for the Treatment of Neuronopathic Gaucher Disease and Expects to Initiate

  2. Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease

    NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL) ("Prevail" or the "Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients

  3. Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation

    NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative

  4. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  5. Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of Directors

    NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative

  6. Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    Opened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinson's Disease Patients with GBA1 Mutations PR001 for Neuronopathic Gaucher Disease and PR006 for Frontotemporal Dementia with GRN Mutations Progressing

  7. Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases

    Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases Companies to partner on process

  8. Prevail Therapeutics to Present at Upcoming October Conferences

    NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL) ("Prevail" or "the Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients

  9. Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes

    NEW YORK, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL) ("Prevail" or "the Company"), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients

  10. Prevail Therapeutics Provides Program Update on PR001 in Parkinson's Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ:PRVL), a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders, today provided an update